Ayse Betul Uslu-Ersoz
Research Subjects
Research Interests
Ayse Betul Uslu-Ersoz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Meliha Meriç Koç
Department of Infectious Diseases and Clinical Microbiology University of Health Sciences, Başakşehir Çam and Sakura City Hospital Istanbul Turkey
3 shared publications - Sibel Bolukcu
Health Sciences University
3 shared publications - Bilge Sümbül
Bezmialem Vakif Univ, Dept Med Microbiol, Fac Med, Istanbul, Turkey
2 shared publications - Asiye Bahar Kaçmaz
Department of Infection Diseases and Clinical Microbiology, American Hospital, Istanbul, Turkey
1 shared publication - Bülent Durdu
Bezmialem Vakif University Faculty of Medicine Istanbul Türkiye
1 shared publication - Dilara Karakuş1 shared publication
Latest Publications
- Open Access
- 29 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (4) , 272
Correction to: Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases
CORRECTION NOTE The original version of this article, unfortunately, contained a mistake. 4h author name (Bilge Sümbül) is missing in the published version. The original article has been corrected. Corrected article: https://doi.org/10.36519/kd.2024.4781
- 29 December 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (4) , 272
Open AccessCorrection to: Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases
CORRECTION NOTE The original version of this article, unfortunately, contained a mistake. 4h author name (Bilge Sümbül) is missing in the published version. The original article has been corrected. Corrected article: https://doi.org/10.36519/kd.2024.4781
- Open Access
- 27 September 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (3) , 154-160
Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases
Objective: His study aimed to evaluate the factors influencing antibody titers and duration of antibody positivity against SARS-CoV-2 in COVID-19 patients followed for a year. Methods: Adult patients diagnosed with COVID-19 between March and August 2020 were included. Patient data, including age, gender, body mass index (BMI), Charlson comorbidity index (CCI), and clinical severity scores, were recorded. Patients were evaluated four times, and quantitative antibody titers were measured. Results: 53.1% of 177 patients were male, with a median age of 47 (IQR=33.5-55). 39.5% had additional comorbidities. Based on clinical severity, 33.3% were mild, 46.9% were moderate, and 19.8% were severe cases. The median intervals at visits were 56. 92, 193, and 371 days. Antibody positivity rates decreased, with 88.7%, 80.8%, 45.9%, and 21.4% at each visit. Median SARS-CoV-2 anti-N IgG titers decreased, particularly at the third visit (p<0.0001). Significant correlations were found between anti-N IgG titers and disease severity. Multivariate analysis showed that as disease severity increased, the probability of antibody positivity at the first and third visits increased approximately 3 to 6 times. Age and CCI score were also independent variables affecting antibody positivity. Conclusion: We observed a significant decrease in anti-N IgG antibody titers, especially after six months, and a considerable decline within one year. Disease severity was the most significant factor affecting antibody positivity, followed by age and CCI score. The study suggests further research to understand the duration of SARS-CoV-2-induced antibodies, seropositivity, and protective immunity.
- 27 September 2024
- Published by Doc Design and Informatics Co. Ltd. in Klimik Dergisi/Klimik Journal
- Vol. 37 (3) , 154-160
Open AccessInvestigation of Factors Affecting IgG Antibody Response in COVID-19 Cases
Objective: His study aimed to evaluate the factors influencing antibody titers and duration of antibody positivity against SARS-CoV-2 in COVID-19 patients followed for a year. Methods: Adult patients diagnosed with COVID-19 between March and August 2020 were included. Patient data, including age, gender, body mass index (BMI), Charlson comorbidity index (CCI), and clinical severity scores, were recorded. Patients were evaluated four times, and quantitative antibody titers were measured. Results: 53.1% of 177 patients were male, with a median age of 47 (IQR=33.5-55). 39.5% had additional comorbidities. Based on clinical severity, 33.3% were mild, 46.9% were moderate, and 19.8% were severe cases. The median intervals at visits were 56. 92, 193, and 371 days. Antibody positivity rates decreased, with 88.7%, 80.8%, 45.9%, and 21.4% at each visit. Median SARS-CoV-2 anti-N IgG titers decreased, particularly at the third visit (p<0.0001). Significant correlations were found between anti-N IgG titers and disease severity. Multivariate analysis showed that as disease severity increased, the probability of antibody positivity at the first and third visits increased approximately 3 to 6 times. Age and CCI score were also independent variables affecting antibody positivity. Conclusion: We observed a significant decrease in anti-N IgG antibody titers, especially after six months, and a considerable decline within one year. Disease severity was the most significant factor affecting antibody positivity, followed by age and CCI score. The study suggests further research to understand the duration of SARS-CoV-2-induced antibodies, seropositivity, and protective immunity.
- 1 February 2021
- Published by Bezmialem Vakif University in Bezmialem Science
- Vol. 9 (1) , 1-3
COVID-19 and Influenza Coexistence
- 1 February 2021
- Published by Bezmialem Vakif University in Bezmialem Science
- Vol. 9 (1) , 1-3
COVID-19 and Influenza Coexistence